News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Juniper Pharma (JNP) To Report Second Quarter 2017 Results On August 3, 2017



7/28/2017 8:16:17 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

BOSTON, July 27, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on August 3, 2017, to discuss the financial results for the second quarter ended June 30, 2017, as follows:

Date:                  Thursday, August 3, 2017

Time:                  4:30 p.m.

Dial-in numbers:  Toll free: (1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or International: (1-412-902-4218)

Audio webcast (live & archive): www.juniperpharma.com, under 'Investors' or click here.

The teleconference replay will be available approximately one hour after completion through Thursday, August 10, 2017, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10110526.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Investor Contact:  
Laura Perry or Heather Savelle
Argot Partners 
212-600-1902
laura@argotpartners.com
heather@argotpartners.com 

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.  
Follow us on
LinkedIn  

View original content:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-second-quarter-2017-results-on-august-3-2017-300495486.html

SOURCE Juniper Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES